Nadia Hamdy (7 results)

Hardcover. Condition: new. Hardcover. This book explores the intricate world of epigenetics and its pivotal role in precision medicine and the identification of epigenetic biomarkers for patient stratification, highlighting the importance of non-coding RNAs (ncRNAs), DNA methylation and histone modifications. The book discusses various epigenetic drugs, such as HDAC inhibitors and DNA methyltransferase inhibitors, targeting specific pathways to provide new therapeutic avenues. An important part in each chapter is dedicated to in silico analysis in epigenetics, including genome-wide association studies to identify correlations between genetic variations and epigenetic changes. It also covers computational models that simulate the effects of epigenetic modifications on cellular behaviour, providing insights into clinical trials with prodrugs in various types of cancer. The book focuses on the crucial role of gut microorganisms in hormone metabolism, synthesis of bioactive compounds and maintenance of the immune response, influencing endocrine homeostasis. It explores the interplay between gut microbiota, ncRNAs and endocrine regulation, focusing on endocrine-related cancers. The impact of the gut microbiome on host health through epigenetic changes is examined in depth, with a particular focus on the role of ncRNAs in host-microbe interactions. Advances in liver cell epigenetics are discussed, showing how epigenetic changes contribute to liver disorders and the potential for epigenetic-based therapeutic approaches. The book also addresses the impact of epigenetic modifications in colorectal cancer and breast cancer highlighting their role in inflammation, vascular function and lipid metabolism. Special attention is given to the importance of epigenetics and precision medicine in the context of rare cancers, blood disorders and immune-related diseases. The book reviews current literature, clinical trials and case studies, providing an overview of therapeutic potentials and innovations. It emphasises the importance of patient-centred approaches, collaborative research networks and ethical considerations in advancing the field. This book synthesises findings on the contributions of epigenetics and precision medicine to the treatment of various diseases, advocating interdisciplinary research and continuing education to improve patient care and outcomes. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.

Buch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - This book explores the intricate world of epigenetics and its pivotal role in precision medicine and the identification of epigenetic biomarkers for patient stratification, highlighting the importance of non-coding RNAs (ncRNAs), DNA methylation and histone modifications. The book discusses various epigenetic drugs, such as HDAC inhibitors and DNA methyltransferase inhibitors, targeting specific pathways to provide new therapeutic avenues.An important part in each chapter is dedicated to in silico analysis in epigenetics, including genome-wide association studies to identify correlations between genetic variations and epigenetic changes. It also covers computational models that simulate the effects of epigenetic modifications on cellular behaviour, providing insights into clinical trials with prodrugs in various types of cancer.The book focuses on the crucial role of gut microorganisms in hormone metabolism, synthesis of bioactive compounds and maintenance of the immune response, influencing endocrine homeostasis. It explores the interplay between gut microbiota, ncRNAs and endocrine regulation, focusing on endocrine-related cancers. The impact of the gut microbiome on host health through epigenetic changes is examined in depth, with a particular focus on the role of ncRNAs in host-microbe interactions.Advances in liver cell epigenetics are discussed, showing how epigenetic changes contribute to liver disorders and the potential for epigenetic-based therapeutic approaches. The book also addresses the impact of epigenetic modifications in colorectal cancer and breast cancer highlighting their role in inflammation, vascular function and lipid metabolism.Special attention is given to the importance of epigenetics and precision medicine in the context of rare cancers, blood disorders and immune-related diseases. The book reviews current literature, clinical trials and case studies, providing an overview of therapeutic potentials and innovations. It emphasises the importance of patient-centred approaches, collaborative research networks and ethical considerations in advancing the field.This book synthesises findings on the contributions of epigenetics and precision medicine to the treatment of various diseases, advocating interdisciplinary research and continuing education to improve patient care and outcomes.

Hardcover. Condition: Brand New. 250 pages. 9.25x6.10x9.49 inches. In Stock.

Condition: new. Questo è un articolo print on demand.

Buch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book explores the intricate world of epigenetics and its pivotal role in precision medicine and the identification of epigenetic biomarkers for patient stratification, highlighting the importance of non-coding RNAs (ncRNAs), DNA methylation and histone modifications. The book discusses various epigenetic drugs, such as HDAC inhibitors and DNA methyltransferase inhibitors, targeting specific pathways to provide new therapeutic avenues.An important part in each chapter is dedicated to in silico analysis in epigenetics, including genome-wide association studies to identify correlations between genetic variations and epigenetic changes. It also covers computational models that simulate the effects of epigenetic modifications on cellular behaviour, providing insights into clinical trials with prodrugs in various types of cancer.The book focuses on the crucial role of gut microorganisms in hormone metabolism, synthesis of bioactive compounds and maintenance of the immune response, influencing endocrine homeostasis. It explores the interplay between gut microbiota, ncRNAs and endocrine regulation, focusing on endocrine-related cancers. The impact of the gut microbiome on host health through epigenetic changes is examined in depth, with a particular focus on the role of ncRNAs in host-microbe interactions.Advances in liver cell epigenetics are discussed, showing how epigenetic changes contribute to liver disorders and the potential for epigenetic-based therapeutic approaches. The book also addresses the impact of epigenetic modifications in colorectal cancer and breast cancer highlighting their role in inflammation, vascular function and lipid metabolism.Special attention is given to the importance of epigenetics and precision medicine in the context of rare cancers, blood disorders and immune-related diseases. The book reviews current literature, clinical trials and case studies, providing an overview of therapeutic potentials and innovations. It emphasises the importance of patient-centred approaches, collaborative research networks and ethical considerations in advancing the field.This book synthesises findings on the contributions of epigenetics and precision medicine to the treatment of various diseases, advocating interdisciplinary research and continuing education to improve patient care and outcomes. 477 pp. Englisch.

Buch. Condition: Neu. From (Epi)genetics-to-Precision (E2P) | Non-protein Coding RNAs (ncRNAs) a Step-toward Precision Medicine | Nadia M. Hamdy (u. a.) | Buch | viii | Englisch | 2026 | Springer | EAN 9783032085290 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand.

Buch. Condition: Neu. This item is printed on demand - Print on Demand Titel. Neuware -This book explores the intricate world of epigenetics and its pivotal role in precision medicine and the identification of epigenetic biomarkers for patient stratification, highlighting the importance of non-coding RNAs (ncRNAs), DNA methylation and histone modifications. The book discusses various epigenetic drugs, such as HDAC inhibitors and DNA methyltransferase inhibitors, targeting specific pathways to provide new therapeutic avenues. An important part in each chapter is dedicated to in silico analysis in epigenetics, including genome-wide association studies to identify correlations between genetic variations and epigenetic changes. It also covers computational models that simulate the effects of epigenetic modifications on cellular behaviour, providing insights into clinical trials with prodrugs in various types of cancer. The book focuses on the crucial role of gut microorganisms in hormone metabolism, synthesis of bioactive compounds and maintenance of the immune response, influencing endocrine homeostasis. It explores the interplay between gut microbiota, ncRNAs and endocrine regulation, focusing on endocrine-related cancers. The impact of the gut microbiome on host health through epigenetic changes is examined in depth, with a particular focus on the role of ncRNAs in host-microbe interactions. Advances in liver cell epigenetics are discussed, showing how epigenetic changes contribute to liver disorders and the potential for epigenetic-based therapeutic approaches. The book also addresses the impact of epigenetic modifications in colorectal cancer and breast cancer highlighting their role in inflammation, vascular function and lipid metabolism. Special attention is given to the importance of epigenetics and precision medicine in the context of rare cancers, blood disorders and immune-related diseases. The book reviews current literature, clinical trials and case studies, providing an overview of therapeutic potentials and innovations. It emphasises the importance of patient-centred approaches, collaborative research networks and ethical considerations in advancing the field. This book synthesises findings on the contributions of epigenetics and precision medicine to the treatment of various diseases, advocating interdisciplinary research and continuing education to improve patient care and outcomes.Springer-Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 488 pp. Englisch.